aiqbench analysis

The article identifies a critical bottleneck in AI-driven drug discovery: current models lack causal biological data derived from living human tissue, relying instead on animal studies or isolated components that fail to predict complex disease outcomes like cancer. To address this gap, the startup Vivodyne is deploying modular robotic labs capable of autonomously generating and monitoring diverse human tissues to provide the high-fidelity datasets necessary for training more accurate predictive models. This shift from theoretical modeling to hardware-enabled data generation represents a tangible infrastructure change required before AI can reliably solve complex biomedical challenges.